Q3 2025 Earnings Call Transcript October 29, 2025 BridgeBio Pharma, Inc. misses on earnings expectations. Reported EPS is $-0 ...
Nitrous oxide (N2O) is a potent greenhouse gas that both traps heat and destroys ozone, reducing Earth's protection from ...
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for ...
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (IPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific ...
Beam Therapeutics Inc. trades at a relatively cheap valuation based on its multiples and potential in SCD. Learn more about ...
Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms ...
Research and Development Expenses -- $9.6 million in the third quarter of 2025, down from $12.3 million in Q3 2024, due to ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that the first patient has been ...
The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit toxicity and elevate patient outcomes. Conventional oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback